» Articles » PMID: 37091842

Gut Microbiota and Oleoylethanolamide in the Regulation of Intestinal Homeostasis

Overview
Specialty Endocrinology
Date 2023 Apr 24
PMID 37091842
Authors
Affiliations
Soon will be listed here.
Abstract

A vast literature strongly suggests that the endocannabinoid (eCB) system and related bioactive lipids (the paracannabinoid system) contribute to numerous physiological processes and are involved in pathological conditions such as obesity, type 2 diabetes, and intestinal inflammation. The gut paracannabinoid system exerts a prominent role in gut physiology as it affects motility, permeability, and inflammatory responses. Another important player in the regulation of host metabolism is the intestinal microbiota, as microorganisms are indispensable to protect the intestine against exogenous pathogens and potentially harmful resident microorganisms. In turn, the composition of the microbiota is regulated by intestinal immune responses. The intestinal microbial community plays a fundamental role in the development of the innate immune system and is essential in shaping adaptive immunity. The active interplay between microbiota and paracannabinoids is beginning to appear as potent regulatory system of the gastrointestinal homeostasis. In this context, oleoylethanolamide (OEA), a key component of the physiological systems involved in the regulation of dietary fat consumption, energy homeostasis, intestinal motility, and a key factor in modulating eating behavior, is a less studied lipid mediator. In the small intestine namely duodenum and jejunum, levels of OEA change according to the nutrient status as they decrease during food deprivation and increase upon refeeding. Recently, we and others showed that OEA treatment in rodents protects against inflammatory events and changes the intestinal microbiota composition. In this review, we briefly define the role of OEA and of the gut microbiota in intestinal homeostasis and recapitulate recent findings suggesting an interplay between OEA and the intestinal microorganisms.

Citing Articles

Harnessing Gut Microbiota for Biomimetic Innovations in Health and Biotechnology.

Beltran-Velasco A, Clemente-Suarez V Biomimetics (Basel). 2025; 10(2).

PMID: 39997096 PMC: 11852373. DOI: 10.3390/biomimetics10020073.


Eight-year diet and physical activity intervention affects serum metabolites during childhood and adolescence: A nonrandomized controlled trial.

Zarei I, Eloranta A, Klavus A, Vaisto J, Lehtonen M, Mikkonen S iScience. 2024; 27(7):110295.

PMID: 39055945 PMC: 11269805. DOI: 10.1016/j.isci.2024.110295.


Shenling Baizhu San ameliorates non-alcoholic fatty liver disease in mice by modulating gut microbiota and metabolites.

Chen D, Wang Y, Yang J, Ou W, Lin G, Zeng Z Front Pharmacol. 2024; 15:1343755.

PMID: 38720776 PMC: 11076757. DOI: 10.3389/fphar.2024.1343755.


Transcriptomic (DNA Microarray) and Metabolome (LC-TOF-MS) Analyses of the Liver in High-Fat Diet Mice after Intranasal Administration of GALP (Galanin-like Peptide).

Takenoya F, Shibato J, Yamashita M, Kimura A, Hirako S, Chiba Y Int J Mol Sci. 2023; 24(21).

PMID: 37958806 PMC: 10648535. DOI: 10.3390/ijms242115825.


Effect of Oleoylethanolamide-Based Dietary Supplement on Systemic Inflammation in the Development of Alimentary-Induced Obesity in Mice.

Ivashkevich D, Ponomarenko A, Manzhulo I, Sultanov R, Dyuizen I Nutrients. 2023; 15(20).

PMID: 37892420 PMC: 10609781. DOI: 10.3390/nu15204345.

References
1.
DiPatrizio N, Piomelli D . Intestinal lipid-derived signals that sense dietary fat. J Clin Invest. 2015; 125(3):891-8. PMC: 4362267. DOI: 10.1172/JCI76302. View

2.
David L, Maurice C, Carmody R, Gootenberg D, Button J, Wolfe B . Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2013; 505(7484):559-63. PMC: 3957428. DOI: 10.1038/nature12820. View

3.
Thabuis C, Destaillats F, Lambert D, Muccioli G, Maillot M, Harach T . Lipid transport function is the main target of oral oleoylethanolamide to reduce adiposity in high-fat-fed mice. J Lipid Res. 2011; 52(7):1373-82. PMC: 3111743. DOI: 10.1194/jlr.M013391. View

4.
Coccurello R, Marrone M, Maccarrone M . The Endocannabinoids-Microbiota Partnership in Gut-Brain Axis Homeostasis: Implications for Autism Spectrum Disorders. Front Pharmacol. 2022; 13:869606. PMC: 9204215. DOI: 10.3389/fphar.2022.869606. View

5.
Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S . Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 2005; 54(10):2838-43. PMC: 2228268. DOI: 10.2337/diabetes.54.10.2838. View